Skip to content
ClinCalc Pro
Menu
Rifamycin Antibiotic (Anti-Biofilm)

Rifampicin 300–600mg BD

Brand names: Rifadin, Rimactane

Rifampicin is a rifamycin antibacterial used in combination regimens for the treatment of bone and joint infections, including prosthetic joint and staphylococcal biofilm-associated infections.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits bacterial DNA-dependent RNA polymerase, suppressing RNA synthesis, and has good penetration into bone and biofilm.

Prescribing in practice

  • It is a potent inducer of hepatic cytochrome P450 enzymes and causes numerous clinically important interactions, including reduced efficacy of warfarin, combined hormonal contraceptives and many other drugs.
  • It must never be used as monotherapy for active infection because resistance emerges rapidly; it is always combined with another active agent.
  • It can cause hepatotoxicity and commonly produces orange-red discolouration of urine, tears and other body fluids.

Monitoring

Monitor liver function and full blood count during therapy, and review concurrent medicines for induction-related interactions.

Counselling the patient

  • Your urine, sweat and tears may turn an orange-red colour, which is harmless but can stain soft contact lenses.
  • Use an additional non-hormonal method of contraception, as this medicine reduces the effectiveness of the contraceptive pill.
  • Report yellowing of the skin or eyes, nausea or unusual tiredness as these may indicate liver problems.

Evidence & guidelines

Guidelines for prosthetic joint infection support rifampicin combination therapy for staphylococcal biofilm-associated infection.

Reference: IDSA PJI Guidelines 2013; BSAC Bone and Joint Infection Guidelines; ESCMID/EFORT Guidelines 2019; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.